Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPRESS: Giredestrant vs Tamoxifen in Early Breast Cancer
NCT05659563Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Jul 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of giredestrant in breast cancer, sponsored by MEDSIR. Started Jul 2023; status: completed.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05659563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05659563.